Physician profile
Michael Miller
NPI 1255394714
$6,512.04
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $574 · 2021: $977 · 2022: $1,147 · 2023: $1,855 · 2024: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,171.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,699.22 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $885.51 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $619.12 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $555.70 | 2019-2024 | Tradjenta, Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $507.46 | 2020-2024 | Jardiance, Mounjaro |
| Abbvie INC. | $425.37 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.84 | 2020-2024 | Xifaxan |
| Daiichi Sankyo INC. | $276.08 | 2019-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $229.52 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $170.69 | 2023 | Auvelity |
| Organon LLC | $160.32 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $135.26 | 2024 | Voquezna |
| Exact Sciences Corporation | $106.54 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $69.59 | 2019-2024 | |
| Astellas Pharma US INC | $62.92 | 2019-2024 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $56.53 | 2020-2021 | |
| Indivior INC. | $47.07 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.66 | 2022 | |
| Allergan, INC. | $27.03 | 2019-2020 | |
| Abbott Laboratories | $17.54 | 2023 | Freestyle Libre 2 |
| Gilead Sciences, INC. | $16.82 | 2019 | |
| Esperion Therapeutics, INC. | $16.63 | 2021 | |
| Biodelivery Sciences International, INC. | $13.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.61 | 2021 | |
| Collegium Pharmaceutical, INC. | $11.87 | 2021 | |
| Eisai INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.